In addition, a novel inhibitor SKI-178, by dual inhibition of SphK1 and S1P lyase, exhibits stronger proliferation-inhibitory effects in various cancer cell lines, providing a potential strategy for overcoming HCC drug resistance (46). Here, SPHK1 is linked to cancer.